Materialise (NASDAQ:MTLS) reported fourth-quarter financial results that showcased the growing dominance of its healthcare division, helping the company achieve a significant jump in profitability despite a mixed macroeconomic backdrop.
The company posted total revenue of €70.2 million for the quarter ended December 31, 2025, a 6.8% increase compared to the prior-year period.
The growth was spearheaded by the Materialise Medical segment, which saw revenue climb 16.3% to a quarterly record.
This surge in medical demand helped lift the company’s consolidated gross profit margin to 58.1%, up from 55.4% a year ago.
On the bottom line, Materialise reported a net result of €6.2 million, or €0.11 per diluted share, more than doubling the €2.9 million profit recorded in the fourth quarter of 2024.
Adjusted EBIT also saw a dramatic turnaround, amounting to €4 million compared to a loss in the previous year’s final quarter.
The final quarter of 2025 was also a milestone for the company’s corporate structure, marked by its successful listing on Euronext Brussels and the launch of a €30 million share buyback program.
As of year-end, Materialise maintained a robust balance sheet with €133.9 million in cash and cash equivalents.
Looking ahead to 2026, Materialise issued an optimistic forecast, targeting full-year revenue between €273 million and €283 million.